title: Dacarbazine mediate antimelanoma effects via NK cells.
abstract: Melanoma is a highly chemoresistant and metastatic tumor that, in the absence ofBRAFmutations, is generally treated with the alkylating agent dacarbazine (DTIC). We discovered that DTIC upregulates the expression of NKG2D ligands on tumor cells, leading to the activation of natural killer (NK) and CD8+T cells. These observations underscore the immunogenic properties of DTIC and provide a rationale to combine DTIC with immunotherapeutic agents.
authors.affiliation: INSERM; U866; Dijon, France ; Dermatology Unit; Dijon-CHU Hospital; Dijon, France ; Université de Bourgogne; Dijon, France.
authors.forename: Alice
authors.initials: A
authors.lastname: Hervieu
authors.forename: Gregoire
authors.initials: G
authors.lastname: Mignot
authors.forename: François
authors.initials: F
authors.lastname: Ghiringhelli
keywords: B16; NK cells; NKG2D; dacarbazine; melanoma